Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Adults With Genotype 1b Hepatitis C Virus (HCV) Without Cirrhosis (GARNET)

NCT02582632 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT02582632
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02582632 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Adults With Genotype 1b Hepatitis C Virus (HCV) Without Cirrhosis (GARNET)
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Completed
Start date
November 24, 2015
Completion date
December 1, 2016
Enrollment
166 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c infection, hepatitis c virus